Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (382)	5/3/2002 2:10:44 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 1022

And with its debt due in '06, it will not be able to put much of the proceeds to work. Nevertheless, the interest income does hide a considerable portion of the burn. And, I would point out the balance sheet values at which it carries its investments ($77m genmab and $48m IDM) are vulnerable. Greatest clinical hopes are for the Aventis ITP Mab and CD4 RA/psoriasis (no raves here, but a contender) which might lead to raising money via genmab liquidation. No longer screamingly overvalued, but with a $447m tech value back loaded with license fees it is not a hand-over-fist buy IMO. Most of the big pharma collaborations were 2001/2000 deals, so those royalties are a long way away. I am holding mine (low basis), but decided not to add at these levels. I want DRUGS! FWIW